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ABSTRACT
Multiple myeloma (MM) is a B cell malignancy that accounts for 10% of all hematologic cancers. In recent
years much has been learned regarding the biology of the myeloma clone; specifically on the chromosomal
alterations that can be more frequently found and on the involved oncogenes. It has been also demonstrated
that, in MM, bone marrow microenvironment, both in its cellular (stromal cells, osteoblasts, osteoclasts,
endothelia) and protein (extracellular matrix) components, plays an important role in promoting growth and
survival of malignant plasma cells. Much of this knowledge will be translated into a better patients treatment;
although high-dose therapy programs can be considered the treatment of choice for patients aged 70 or
younger, novel drugs, targeting MM clone in its microenvironment can be incorporated into these therapeutic
programs improving response rate and patients survival.
© 2006 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Multiple myeloma (MM) is a B-cell malignancy
haracterized by proliferation and accumulation of B
ymphocytes and plasma cells, secreting monoclonal im-
unoglobulins, in the bone marrow and, less frequently,
t extramedullary sites [1]. MM accounts for more than
0% of all hematologic malignancies. The male-female
atio is 1.5:1, and the median age at diagnosis is 70 years
2]. Clinical symptoms at diagnosis include bone pain as
result of osteolytic lesions or fractures; fatigue due to
nemia; renal failure; and recurrent infections. Periph-
ral neuropathy, bleeding, and hyperviscosity syndrome
re less commonly observed [3]. Bone marrow aspirate
hows 30% monoclonal plasma cells, and serum or
rine monoclonal protein can be detected in 97% of
he patients, whereas in 3% of cases no monoclonal
rotein component can be identiﬁed with conventional
aboratory investigations. This percentage further de-
reases when the more sensitive immunoglobulin free-
ight chain assay is used. Criteria for the classiﬁcation of
onoclonal gammopathies, MM, and related disorders
ave been provided elsewhere [4]. The clinical course of
he disease is extremely variable but progressive; through
he years, many prognostic factors have been identiﬁed p
B&MThat are either related to patient characteristics (poor
erformance status or renal failure) or related to the
isease burden and activity (2-microglobulin, C-reac-
ive protein, and plasma cell labeling index). Recently,
he International Myeloma Foundation promoted data
ollection from 11 000 patients from Asia, America,
nd Europe; a staging system was thus proposed that was
ased on 2-microglobulin and serum albumin. Three
isk groups with signiﬁcantly different survival can be
dentiﬁed [5] (Table 1). Furthermore, cytogenetic ab-
ormalities seem to be increasingly important in deﬁn-
ng patients’ prognosis, as will be described in the fol-
owing section.
HE MYELOMA CLONE
The genetic basis of the pathogenesis of MM is
ot unique; neoplastic cells can show a hyperdiploid
aryotype with rare translocations or other structural
bnormalities or a nonhyperdiploid karyotype with
hromosomal translocations that frequently involve
he immunoglobulin heavy-chain locus (IgH; 14q32).
hese alterations, which are often cryptic for conven-
ional cytogenetics, involve different chromosomal
artners, some of which are common to other B-cell
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8eoplastic disorders, such as the 11q23 locus, where
he BCL1/cyclin D1 oncogene is located. Conversely,
ther chromosomal partners, such as 4p16.3, 6p21,
nd 16q23, seem to be peculiarly involved in MM. As
consequence of the chromosomal translocations out-
ined previously, the proto-oncogenes located on the
artner chromosome of 14q32 (BCL1/cyclin D1, FGFR3,
yclin D3, and c-maf) are placed under transcriptional
ontrol of the potent IgH enhancer, thus resulting in
heir overexpression. Although the biologic signiﬁ-
ance of the overexpression of the different proto-
ncogenes in the framework of MM pathogenesis is
resently under investigation, it seems now clear that
ome of the chromosomal alterations described previ-
usly do possess prognostic implications. A better
rognosis is observed in patients carrying the t(11;
4)(q13,q32) alteration [6], whereas t(4;14)(p16.3,q32) is
n unfavorable prognostic factor [7]. In the telomeric
egion of the short arm of chromosome 4 are several
utative transcriptional units containing the MMSET,
ACC3, and LETM1 genes; of these, MMSET seems to
osses a major role in favoring the clonal expansion of
alignant cells. A poor prognosis is also associated
ith chromosome 13 deletion, which can be detected
n 50% of patients by interphase ﬂuorescence in situ
ybridization analysis [7]. Genetic alterations that are
ost frequently found in MM are reported in Table 2.
o cytogenetic marker can distinguish monoclonal
ammopathies of undetermined signiﬁcance (MGUS)
rom MM; however, it has been hypothesized that in
M, as in other tumors, the dysregulation of onco-
enes and tumor-suppressor genes controlling cell pro-
iferation, growth arrest, and apoptosis contributes to
he progression of the disease. Secondary chromosomal
ranslocations involving c-myc, activating mutations of
he family of ras oncogenes (n-ras and k-ras), muta-
ion, or monoallelic p53 deletions are extremely rare
n MGUS or smoldering MM, whereas the highest
requency occurs in advanced phases of MM. This
nding lends support to the notion that these genetic
lterations can play a role in driving the progression
f MM.
A consistent advance in understanding the biology
f MM is presently being obtained through the eval-
ation of gene expression proﬁling; this technology
as allowed identiﬁcation of genes differently expressed
n normal versus malignant plasma cells [8] to separate
able 1. International Staging System for Multiple Myeloma
Stage Parameters
Median
Survival (mos)
I 2-Microglobulin <3.5 mg/L
and albumin >3.5 mg/dL
62
II No I or III 44
III 2-Microglobulin >3.5 mg/L 29M patients into different subgroups whose gene *
2xpression proﬁling pattern is related to cytogenetic
bnormalities, clinical picture, and response to ther-
py [9] and to provide insights into the mechanism of
esponse or resistance to different drugs [10].
M-MICROENVIRONMENT CROSS TALK
It has been recently demonstrated that cellular
stromal cells, osteoclasts, and osteoblasts) and protein
extracellular matrix) components of the bone marrow
icroenvironment play a crucial role in the pathogen-
sis of MM. It is well known, for example, that adhe-
ion to extracellular matrix confers resistance to FAS-
ediated apoptosis to neoplastic plasma cells [11]. Even
ore important for the pathogenesis, growth, and
rogression of MM is adhesion of plasma cells to bone
arrow stromal cells that induce transcription and
ecretion of cytokines (interleukin [IL]–6, insulin-like
rowth factor 1, and tumor necrosis factor ) that
ediate cell proliferation and migration, together with
echanisms that control drug resistance and apoptosis.
n particular, IL-6 is the major growth factor of MM,
nd it promotes proliferation, elicits dexamethasone re-
istance, and induces expression and secretion of vascular
ndothelial growth factor (VEGF) in neoplastic plasma
ells [12].
In MM patients, bone marrow angiogenesis is
emarkably increased as compared with what is ob-
erved in MGUS, and it is well known that patients
ith nonactive MM (complete or partial remission
plateau phase]) show reduced bone marrow angio-
enesis in comparison to patients with active disease
newly diagnosed MM, relapse phase, or plasma cell
eukemia) [13]. Neoplastic plasma cells induce their
wn microvascular system through the secretion of
broblast growth factor 2 and enzymes that display
roteolytic activity on the matrix, such as metallopro-
einases 2 and 9 and urokinase-type plasminogen ac-
ivator. VEGF, however, plays a central role in the in-
uction of bone marrow angiogenesis in MM, because
essenger RNA encoding VEGF has been identiﬁed in
lasma cells from MM patients and in MM cell lines.
urthermore, VEGF can in turn induce the secretion of
L-6 by bone marrow stromal cells, so a paracrine and
able 2. Chromosomal Abnormalities in MM
Alteration Method % Patients Prognosis
13 Conventional 10-20 Adverse
FISH 30-35 Adverse*
gH translocations
t(11;14) Conventional/FISH 15-20 Good*
t(4;14) FISH 15-20 Adverse
t(14;16) FISH 2-10 Adverse
ISH indicates ﬂuorescence in situ hybridization.
Still under debate.
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Butocrine mechanism supporting plasma cell growth can
e hypothesized [14].
Skeletal involvement is observed in approximately
0% of patients with newly diagnosed MM; this com-
lication is attributed to an alteration in the mecha-
isms of bone remodeling induced by neoplastic
lasma cells, as demonstrated by in vitro coculture
xperiments [15], so that bone resorption is promoted
osteoclast activity) and bone formation is inhibited
osteoblast activity). It is well known that osteoclasts
re recruited and undergo normal maturation through
he interaction of their receptor RANK (receptor ac-
ivator of nuclear factor-B) with its ligand (RANK-L)
roduced by stromal cells, preosteoblasts, and activated
lymphocytes. The activity of RANK-L is balanced by
he presence of its decoy receptor, osteoprotegerin,
hich is produced by stromal cells and preosteoblasts
16]. In MM, osteoclast activity is promoted by an in-
reased production of RANK-L by stromal cells and
reosteoblasts, a reduced production of osteoprotegerin,
nd an upregulation of pro-osteoclastogenic cytokines,
uch as IL-1, macrophage colony-stimulating factor,
nd macrophage inﬂammatory protein 1 [15,16]. The
ctivity of osteoblasts is concomitantly reduced; in fact,
alignant bone marrow plasma cells express and secrete
he soluble wnt inhibitor DKK-1, which could poten-
ially impair the maturation of osteoblasts [17]. Oste-
clasts can in turn promote plasma cell growth
hrough an increased production of IL-6 [18], thus
ontributing to the maintenance of the vicious circle.
M THERAPY
utologous Stem Cell Transplantation
High-dose chemotherapy followed by autologous
tem cell transplantation is presently the treatment of
hoice for MM patients younger than 60 to 65 years.
his recommendation derives from the results of 2
rospective randomized studies [19,20] that have
emonstrated that single autologous stem cell trans-
lantation is superior to conventional chemotherapy
ecause it results in a signiﬁcantly longer patient sur-
ival. To further improve these results, 2 sequential
ines of high-dose chemotherapy followed by double
utologous stem cell transplantation have been ap-
lied; the clinical advantage obtained with this proce-
ure, as compared with a single transplantation, has
een recently demonstrated by 2 prospective random-
zed studies [21,22] that showed a longer response
uration and disease-free survival in patients treated
ith double autologous stem cell transplantation. A
urvival advantage is mostly evident in patients who
ere primarily refractory to conventional induction
hemotherapy and in those who did not reach com-
lete remission either after the ﬁrst transplantation or
t the end of the entire therapeutic program to which c
B&MThey were assigned (single or double autologous stem
ell transplantation). Autologous stem cell transplan-
ation has been also used in patients with MM and
hronic renal failure; because of the higher incidence
f complications, an appropriate dose reduction has
een proposed. Results are encouraging in terms of
reatment-related mortality and survival [23].
ovel Therapies
In addition to the clinical beneﬁt offered by a
ouble autologous stem cell transplantation, the ther-
peutic strategies for MM can be improved by the
vailability of drugs that are active both on neoplastic
lasma cells and on the bone marrow microenviron-
ent. Thalidomide, a glutamic acid derivative with
edative properties, has been demonstrated to be able
o induce an objective response in 30% to 40% of
atients with advanced, relapsed, or refractory MM
24], and it is presently proposed as ﬁrst-line therapy
n patients with newly diagnosed disease and, in com-
ination with dexamethasone or conventional chemo-
herapy, as preparation for high-dose therapy programs
25,26]. The mechanism of action of thalidomide has not
et been fully elucidated. Although this compound is a
otent inhibitor of angiogenesis, its activity in MM
nd other hematologic disorders is more likely to be
ue to its interaction with bone marrow stromal cells
nd to the subsequent inhibition of the secretion of
umor necrosis factor  and IL-6 and to the down-
egulation of adhesion molecules. Furthermore, tha-
idomide modulates the immune system, promoting
he growth of natural killer and T lymphocytes and
ncreasing the production of IL-2 and interferon . A
ajor drawback of thalidomide is represented by its
ide effects: more than half of the patients complain of
ethargy and constipation, deep venous thromboses
ccur in up to 15% to 20% of newly diagnosed pa-
ients treated with thalidomide/dexamethasone unless
roper prophylaxis is administered, and World Health
rganization grade 2 peripheral neuropathy is re-
orted in 60% of patients treated longer than 1 year.
Thalidomide analogues were synthesized to obtain
ompounds displaying an antineoplastic activity com-
arable or superior to that of thalidomide, but with
ewer side effects. Lenalidomide (Revlimid; CC5013;
elgene, Warren, NJ) is at present the most widely
ested thalidomide analogue; in a phase II study per-
ormed in 222 patients [27], an objective (or better)
esponse was observed in 28% of the cases, and, im-
ortantly, the incidence of neuropathy was markedly
educed as compared with what has been described in
halidomide-treated patients. Proteasome inhibitors
re another class of drugs that act both on MM clones
nd on the microenvironment. The proteasome is a
ulticatalytic protease that degrades 80% of intra-ellular proteins and, speciﬁcally, cell cycle–regulatory
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8roteins, oncogenes, tumor-suppressor genes, tran-
criptional activators, and inhibitors. Neoplastic cells
nd, in particular, MM cells are very sensitive to pro-
easome inhibitors because the subsequent accumula-
ion of regulatory proteins leads to cell-cycle arrest
nd apoptosis. Bortezomib, a boronic acid derivative,
s the proteasome inhibitor that has so far been re-
ealed as the most promising in vitro and has been
ubsequently widely used in the clinic; 30% objec-
ive responses have been obtained in patients with
elapsed/refractory disease [28]. Also, in a multicenter
andomized trial conducted in 669 relapsed MM pa-
ients, a signiﬁcantly higher response rate (38% versus
8%) and a longer time to progression and survival
ere observed, as compared with high-dose dexa-
ethasone [29].
llogeneic Stem Cell Transplantation
Myeloablative allogeneic bone marrow transplan-
ation (allo-BMT) for the treatment of MM was in-
roduced in the early 1980s by several institutions [30].
onventional preparative regimens consisted of total
ody irradiation (10 Gy with lung shielding) or, less
requently, high-dose busulfan [31] plus high-dose
yclophosphamide or melphalan. This procedure was
nitially offered to heavily pretreated patients with
dvanced refractory disease, and despite a treatment-
elated mortality exceeding 40%, it allowed demon-
tration that high-dose chemotherapy/radiotherapy cou-
led with a graft-versus-myeloma (GVM) effect could
vercome drug resistance and induce long-lasting com-
lete remission. Transplant-related mortality (TRM),
owever, remained a major issue for almost 10 years:
ost trials reported mortality rates ranging from 37% to
7%. A retrospective case-matched study performed
y the European Group for Blood and Marrow Trans-
lantation in 1996 [32], aimed at comparing the out-
ome of MM patients who underwent autologous or
llogeneic stem cell transplantation between 1983 and
994, showed that survival was poorer in the al-
ografted group as a result of a signiﬁcantly higher
RM (41% versus 13%).
A comparison of myeloablative transplantation re-
orted by the European Group for Blood and Marrow
ransplantation registry during 2 time periods (1983-
993 and 1994-1998), however, showed a signiﬁcant
eduction in TRM during the later time period (21%
ersus 38% observed before 1994) [33]. This can be
ttributed to an improvement in patient care, because
ore effective bacterial, fungal, and viral treatments
ere made available through the years, whereas the
ncreasingly frequent use of peripheral blood as a stem
ell source did not seem to favorably affect patient
utcome. Favorable prognostic factors for survival af-
er myeloablative allo-BMT in MM are younger age,
ow 2-microglobulin, stage I disease at diagnosis, and r
4hemosensitive disease; the relapse rate, however, does
till average 30%, and this raises the issue of whether
llo-BMT can potentially cure MM.
To address this, we have retrospectively analyzed
he presence of minimal residual disease in serial post-
ransplantation bone marrow samples obtained from
atients in sustained complete remission after allogeneic
tem cell transplantation [34] For this purpose, pa-
ient-speciﬁc primers were generated from comple-
entarity-determining regions 2 and 3 of the rear-
anged IgH gene; it was found that 75% of the patients
ho were analyzed remained persistently polymerase
hain reaction negative for a median of 3 years, with
ome polymerase chain reaction–negative patients at 4
o 10 years after allogeneic stem cell transplantation.
t can thus be concluded that allogeneic stem cell
ransplantation is associated with a GVM effect that
esults in more frequent molecular complete re-
ponses and a decreased probability of relapse as com-
ared with autologous stem cell transplantation [35].
herefore, allogeneic stem cell transplantation is
robably the only therapeutic approach that has the
otential ability to eradicate the myeloma clone; how-
ver, presently available results do not allow its con-
ideration as the treatment of choice for MM. The
hallenge for clinical investigators will be to further
educe TRM by an improved patient selection and
etter supportive care and to increase the complete
esponse rate. A decrease in TRM could be achieved
y the use of nonmyeloablative preparative regimens
reduced intensity conditioning-allo-BMT) aimed at
educing conditioning-related toxicity while sparing
he GVM effect. A great variety of preparative regi-
ens have been proposed that include either low-dose
2 Gy) total body irradiation with ﬂudarabine or in-
ermediate-dose melphalan plus ﬂudarabine. A favor-
ble outcome is more frequently observed in non–
eavily pretreated patients and in chemosensitive
isease [36]. Presently, a tandem strategy of high-dose
elphalan and autologous stem cell transplantation fol-
owed by reduced intensity conditioning-allo-BMT is
eing used by several groups to further decrease the
umor burden before inducing a GVM effect. Mature
ata evaluating the long-term outcome of this strategy
ill be available soon.
upportive Therapy
The global treatment approach to MM should also
nclude supportive therapy; the main ﬁelds of inter-
ention include treatment of anemia, prevention of
nfections, and treatment/prevention of bone disease.
nemia is present in almost two thirds of patients at
iagnosis: it improves when disease is controlled by
reatment, and it worsens in progressive or resistant
isease. After exclusion of iron or vitamin deﬁciency,
ecombinant erythropoietin should be used, because it
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Bncreases the hemoglobin concentration, reduces trans-
usion requirements, and improves quality of life. Pa-
ients with a hemoglobin level 10 g/dL should re-
eive erythropoietin at a dose of 10 000 U 3 times a
eek or 30 to 40 000 U once a week [37]. Alterna-
ively, darbepoetin  can be used, at 150 g/wk. In-
ections are a primary cause of death in MM, and risk
ncreases during chemotherapy, long-term therapy
ith steroids, and autologous and, above all, alloge-
eic stem cell transplantation. Intravenous immuno-
lobulins should not be routinely used as general pro-
hylaxis for bacterial infection in MM patients; their
se should be reserved for patients with recurrent infec-
ions and polyclonal hypogammaglobulinemia and for
ecipients of allogeneic stem cell transplants showing
evere hypogammaglobulinemia. Prophylactic antibi-
tics should not be routinely used during conventional
hemotherapy; trimethoprim-sulfamethoxazole is rec-
mmended to prevent Pneumocystis carinii pneumonia
n patients treated with high-dose dexamethasone. Sea-
onal inﬂuenza vaccination should be recommended for
ll MM patients, whereas Haemophilus inﬂuenzae type B
accine and 23-valent pneumococcal polysaccharide
accine should be used in patients treated with autol-
gous or allogeneic stem cell transplantation [37].
keletal involvement is a common feature of MM. Up
o 80% of newly diagnosed MM patients present with
steopenia, osteolysis, and pathologic fractures, and
he latter can severely impair patients’ quality of life.
isphosphonates are presently the only clinically
vailable drugs capable of inhibiting osteoclast activ-
ty; MM patients with bone lesions or severe osteopenia
hould thus be treated with bisphosphonates. These
ompounds have been proven to reduce skeletal-re-
ated events and bone pain both in early-stage and
dvanced disease [37]. Because absorption after oral
dministration is poor, intravenous treatment should
e preferred, either with pamidronate 90 mg/4 weeks
n at least a 2-hour infusion or with zoledronic acid 4
g/4 weeks in a 15-minute infusion.
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